Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
PREDNISOLONE

PREDNISOLONE

Send Inquiry
Product: PREDNISOLONE
Formulary: Generic Formulary
Category: Endocrine System
Sub Group: CORTICOSTEROIDS
Dosages: 4MG /16 MG
Unit of Packing: Tablets
In treatment of: Suppression of allergic and inflammatory responses,bronchial asthama,severe dermatological reactions

 Adverse Effects: 

  • Susceptibility to infection
  • Peptic ulcer
  • Haemorrhage
  • Glycosuria
  • Hyperglycaemia
  • Osteoporosis
  • Atrophy of adrenal cortex(on prolonged therapy)
  • Suppression of adrenocorticotropic hormone
  • Cushing`s syndrome
  • Inhibition of growth in children
  • Amenorrhoea
  • Behavioral disturbances
  • Thromboembolic disorders
  • Myopathy
  • Weakness
  • Lymphocytopenia
  • Muscle wasting
  • Gastrointestinal discomfort
  • Increased appetite
  • Delayed wound healing
  • Headache
  • Euphoria
  • Insomnia
  • Seizures
  • Heart failure
  • Arrhythmias
  • Posterior sub capsular cataract
  • Glaucoma
  • Increased intracranial pressure

Contraiindication: 

  • Hypersensitivity to the drug
  • Peptic ulcer
  • Systemic Infections
  • Fungal infections
  • Live vaccines

Special Precaution: 

  • Avoid sudden discontinuation of the drug
  • Tuberculosis
  • Osteoporosis
  • Ocular herpes simplex
  • Primary glaucoma
  • Peptic ulcer
  • Primary psychosis and psychoneurosis
  • Recent myocardial infarction
  • Heart failure
  • Diabetes mellitus
  • Hypothyroidism
  • Cirrhosis
  • Stress
  • Sepsis
  • Hypertension
  • Myasthenia gravis
  • Renal impairment
  • Hepatic impairment
  • Non specific Ulcerative colitis
  • Diverticulitis
  • Recent intestinal anastomosis
  • Seizures
  • Thromboembolic disorders

Interaction: Barbiturates: Decrease pharmacologic of prednisolone. Oral contraceptives: May increase concentration of prednisolone. Oestrogens: May decrease the clearance of prednisolone. Ketoconazole: Increases efficacy of prednisolone. Rifampicin: Decreases efficacy. Prednisolone affects the actions of the following: Anticholinesterases: Effects may be antagonised in myasthenia gravis. Cyclosporine: May lead to enhanced toxicity. Digitalis glycosides: May lead to enhanced toxicity. Isoniazid: Decreased serum levels of isoniazid. Salicylates: Decreased serum levels of salicylate. Diuretics: May cuase hypokalaemia and increased hyperglycaemia. Non-depolarising muscle relaxants: Altered response. Somatrem: Growth promoting effect inhibited. Theophyllines: Altered response of either agent. IUCD: contraceptive failure. Lab. Tests: a) Increases serum cholesterol levels. b) Increases urine glucose levels. c) Decreases Thyroid I131 uptake; Decreases T3 serum levels. d) Decreases serum potassium.

Servings: Oral: 10 to 60mg/day; depending up on the severity of the condition and patient`s response. Children: 0.15 to 2mg/kg/day in 4 to 6 divided doses; depending up on the severity of the condition and patient`s response. I.M. or I.V.: 2 to 30mg 12th hourly Intra-articular: 5 to 25mg Prednisolone acetate.